Ελληνικά
×
Pharmaceutical Services
Directors's Message
Mission and Responsibilities
Organisation Chart
Annual Report
Accreditation
Responsibilities
Regulatory
Marketing Authorisations for Medicinal Products
Post-approval procedures
Withdrawals
Submission/Validation of applications
Search for Medicinal Products for Human Use
Pharmacovigilance and Clinical Trials
Pharmacovigilance
Clinical Trials
Yellow Carrd
GMDP Inspectorate
Manufacture/Import from third countries Licence
Wholesale Licence
Medicinal Product Brokerage
Qualified Persons
Pharmacovigilance Inspections
Safety Features
Medicinal Products Pricing
Pricing Policy
Price List of Medicinal Products
Co-payment scheme for medicinal products
Price List Updates
Pharmacy Inspections - Pharmacist Registration
Pharmacies
Pharmacists
Annual Leave Pharmacies - Pharmacists
Narcotics, Psychotropics and Drug Precursors
Narcotics and Psychotropics
Drug Precursors
Cosmetics
Manufacturing Licences
Import of cosmetics
Labelling of cosmetics
Product Information File for Cosmetics
Cosmetics Notifications (CPNP)
Councils - Cyprus and EU Committees
Councils - Committees Cyprus
Participations in European and Other Committees
Legislation
European Regulations - Directives
Laws - Regulatory Administrative Acts
Circulars - Guidelines
Latest News
Cross-border prescriptions
Press releases
Events - Activities
Publications
Job Opportunities
Applications
Fees
Announcements
Media Gallery
COVID-19
CY RMS
Yellow Card
Recalls of Medicinal Products
On-Call Pharmacies
Announcements
Press Release
Applications
Fees
e-services / Drug Search
ΚΟΕΦ (CyMVO)
Price List of Medicinal Products
JCC payment
Office of Medicinal Cannabis
Online Pharmacy - Logo
Councils - Committees Cyprus
Cross-border prescriptions
News
- 17/02/2023
CHESSMEN, the Joint Action to mitigate medicine’s shortages
- 01/02/2023
Quick Guide on CTR
- 24/11/2022
EMA recommends approval of VidPrevtyn Beta as a COVID-19 booster vaccine
- 23/11/2022
EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders
- 02/11/2022
EMA recommends approval of Comirnaty and Spikevax COVID-19 vaccines for children from 6 months of age
- 02/11/2022
EMA recommends approval of second adapted Spikevax vaccine
- 02/11/2022
EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders
- 21/09/2022
EMA recommends standard marketing authorisations for Comirnaty and Spikevax COVID-19 vaccines
- 13/09/2022
Adapted vaccine targeting BA.4 and BA.5 Omicron variants and original SARS-CoV-2 recommended for approval
- 09/09/2022
ECDC-EMA statement on booster vaccination with Omicron adapted bivalent COVID-19 vaccines